This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cote GJ and Gagel RF (2003) Lessons learned from the management of a rare genetic cancer. N Engl J Med 349: 1566–1568
De Groot JW et al. (2006) RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27: 535–560
Wohllk N et al. (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81: 3740–3745
Learoyd DL and Robinson BG (2005) Do all patients with RET mutations associated with multiple endocrine neoplasia type 2 require surgery? Nat Clin Pract Endocrinol Metab 1: 60–61
Carlomagno F et al. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284–7290
Acknowledgements
The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Learoyd, D., Robinson, B. Does genetic screening increase detection of familial medullary thyroid cancer in apparently sporadic cases?. Nat Rev Endocrinol 4, 132–133 (2008). https://doi.org/10.1038/ncpendmet0722
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0722